Brief: Noxopharm To Prioritise Allocation Of Resources To Development Of Chromatm And Sofratm Program
06/04/2023 02:05
April 6 (Reuters) - Noxopharm Ltd NOX.AX :
* DETERMINED TO PRIORITISE ALLOCATION OF RESOURCES TO
DEVELOPMENT
OF CHROMATM AND SOFRATM PROGRAMS
* DETERMINED TO LIMIT FURTHER INVESTMENT INTO VEYONDA
CLINICAL
TRIALS BY DISCONTINUING DARRT-2 AND CEP-2 TRIALS
Source text for Eikon: ID:nASX941HkV
Further company coverage: NOX.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Noxopharm
See all newsBrief: Noxopharm Announces SOF-SKN Manufacturing Begins To Ensure Clinical Trial Readiness
Australia's Noxopharm rises as novel cancer therapy shows potential
Brief: Noxopharm Says New Data Confirms Cancer-Fighting Potential
Brief: Noxopharm Appoints Dr Olivier Laczka As New CEO
Brief: Noxopharm Ltd Announces Resignation Of Chief Executive Officer